Trial · NCT00867100
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part B: PASI (Psoriasis Area and Severity Index) Score Mean Percentage of Change Through Day 43 | Placebo | 19.88 | Standard Deviation 6.36 | percentage improvement | |
| Part B: PASI (Psoriasis Area and Severity Index) Score Mean Percentage of Change Through Day 43 | 140 mg Sc | 17.74 | Standard Deviation 15.34 | percentage improvement | |
| Part B: PASI (Psoriasis Area and Severity Index) Score Mean Percentage of Change Through Day 43 | 350 mg Sc | 53.57 | Standard Deviation 30.45 | percentage improvement | |
| Part B: PASI (Psoriasis Area and Severity Index) Score Mean Percentage of Change Through Day 43 | 700 mg IV | 86.04 | Standard Deviation 8.70 | percentage improvement | |
| Part B: All Treatment Adverse Events Reported for Safety Evaluation | Placebo Part B | 4 | participants with events | ||
| Part B: All Treatment Adverse Events Reported for Safety Evaluation | 140 mg Sc Part B | 3 | participants with events | ||
| Part B: All Treatment Adverse Events Reported for Safety Evaluation | 350 mg Sc Part B | 7 | participants with events | ||
| Part B: All Treatment Adverse Events Reported for Safety Evaluation | 700 mg IV Part B | 8 | participants with events | ||
| Part A: All Treatment Adverse Events Reported for Safety Evaluation | Placebo Part A | 14 | participants with events | ||
| Part A: All Treatment Adverse Events Reported for Safety Evaluation | Cohort 1: 7mg SC Part A | 6 | participants with events | ||
| Part A: All Treatment Adverse Events Reported for Safety Evaluation | Cohort 2: 21mg SC Part A | 6 | participants with events | ||
| Part A: All Treatment Adverse Events Reported for Safety Evaluation | Cohort 3: 21mg IV Part A | 3 | participants with events | ||
| Part A: All Treatment Adverse Events Reported for Safety Evaluation | Cohort 4: 70mg SC Part A | 6 | participants with events | ||
| Part A: All Treatment Adverse Events Reported for Safety Evaluation | Cohort 5: 210mg SC Part A | 6 | participants with events | ||
| Part A: All Treatment Adverse Events Reported for Safety Evaluation | Cohort 6: 210mg IV Part A | 4 | participants with events | ||
| Part A: All Treatment Adverse Events Reported for Safety Evaluation | Cohort 7: 420mg SC Part A | 5 | participants with events | ||
| Part A: All Treatment Adverse Events Reported for Safety Evaluation | Cohort 8: 700mg IV Part A | 6 | participants with events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00867100/results